Use of tenascin-c as an extracellular marker of tumor-derived microparticles
AssigneeNX Pharmagen
InventorsAlan M. EZRIN, Steven G. GRIFFITHS
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for isolating tumor-derived microparticles from a subject for analysis, specifically by isolating Tenascin-C positive microparticles from a sample from the subject to obtain tumor-derived microparticles. Methods for determining the expression status of biomarkers in the tumor-derived microparticles and methods for determining additional characteristics of the tumor-derived microparticles are also provided.
Claims35
A method of isolating tumor-derived microparticles from a subject for analysis, the method comprising:
- providing a sample comprising bodily fluid from a subject;
- isolating one or more microparticles from the sample;
- and
- isolating one or more Tenascin-C positive microparticles from the one or more microparticles in the sample to obtain tumor-derived microparticles.
A method of identifying tumor-derived microparticles from a subject for analysis, the method comprising:
- providing a sample comprising bodily fluid from a subject;
- isolating one or more microparticles from the sample;
- and
- identifying one or more Tenascin-C positive microparticles from the one or more microparticles in the sample to identify tumor-derived microparticles.
A method of isolating brain tumor-derived microparticles from a subject for analysis, the method comprising:
- providing a sample comprising bodily fluid from a subject;
- isolating one or more microparticles from the sample;
- and
- isolating one or more Tenascin-C positive microparticles from the one or more microparticles in the sample via immunopurification to obtain brain tumor-derived microparticles.
A method of diagnosing brain cancer in a subject, the method comprising:
- providing a sample comprising bodily fluid from a subject;
- isolating one or more microparticles from the sample;
- isolating one or more Tenascin-C positive microparticles from the one or more microparticles in the sample to obtain tumor-derived microparticles;
- determining the expression status of one or more biomarkers in the tumor-derived microparticles;
- and
- diagnosing brain cancer in the subject based on the expression status of the one or more biomarkers.
Dependencies are inferred from the claim text.